Pulmonary Circulation最新文献

{"title":"Patient Perspectives on Fixed Dose Combination Therapy for Pulmonary Arterial Hypertension: Exploratory Focus Group Research.","authors":"Jean M Elwing, Stacey Barta, Tim Smith, Gabriela Gomez Rendon, David Lopez, Wesley Peters, Marinella Sandros, Akshay Muralidhar","doi":"10.1002/pul2.70098","DOIUrl":"10.1002/pul2.70098","url":null,"abstract":"<p><p>Pulmonary arterial hypertension (PAH) requires lifelong medication, with patients taking an average of 12 tablets/day. Several chronic diseases can be treated with a fixed-dose combination (FDC) tablet, decreasing patient pill burden and increasing adherence. This exploratory research, conducted via focus groups, asked 13 patients with PAH for their insights about the use of FDC (2 PAH treatments in a single tablet), its potential benefits, and challenges to its use. At the time of the focus groups (July 2023), no FDC medications were available for PAH and the discussions were therefore hypothetical. Focus group transcripts were analyzed by a qualitative research specialist to identify key themes. Most participants were unfamiliar with FDC prior to taking part in the focus groups; however, during the engagement, 12/13 participants expressed interest in taking FDC as single-tablet therapy for their PAH. In general, participants saw the potential benefits as improved convenience, less time spent navigating insurance coverage, and improved adherence. Participants felt that reducing their tablet count by just one tablet would be meaningful to them. Concerns were raised about the potential difficulty with medication titration and challenges distinguishing between the side effects of two combined medications. This exploratory research provides insight into the perceptions of US patients on the utility of FDC in PAH and highlights an unmet need for patient education on medication adherence in PAH.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70098"},"PeriodicalIF":2.2,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Daily Walking Bouts as Valid and Reliable Indicators of Exercise Capacity in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).","authors":"Rana Zia Ur Rehman, Federico Parisi, Noman Ashraf, Meenakshi Chatterjee, Robert P Frantz, Anna R Hemnes, Nikolay V Manyakov, Oscar M Carrasco-Zevallos, Tarik Yardibi, Mona Selej, Tommaso Mansi, Preston Dunnmon, Dzmitry A Kaliukhovich","doi":"10.1002/pul2.70097","DOIUrl":"10.1002/pul2.70097","url":null,"abstract":"<p><p>There is a need for objective, continuous and remote assessment of exercise capacity in patients with pulmonary arterial hypertension (PAH). Using data from the TRACE study, in which 108 adult patients with PAH were continuously monitored with a wrist-worn accelerometer, we evaluated whether actigraphy can facilitate continuous monitoring of exercise capacity. Distributions of step rate, distance and duration of patient's walking bouts were estimated at baseline, Week 16 and Week 24 using 2-week periods of actigraphy data. Twenty-one metrics per walking bout characteristic were described (mean, standard deviation, 19 percentiles [5th-95th]). The relationships between these metrics and the 6-min walk distance (6MWD), Borg dyspnea index (BDI), and the PAH Symptoms and Impact questionnaire (PAH-SYMPACT) Physical Impact domain score were assessed at the three timepoints. Test-retest reliability, and discriminant and known-group validity of each metric were also evaluated. All metrics of step rate and bout distance were significantly correlated with 6MWD (Pearson's correlation coefficients: 0.34-0.67; <i>p</i> < 0.005) and the PAH-SYMPACT Physical Impact domain score (Pearson's correlation coefficients: -0.51 to -0.32; <i>p</i> < 0.05) at all timepoints. Negative correlations were also observed with the BDI and the actigraphy-derived metrics, with the majority reaching significance. Strong test-retest reliability was demonstrated (intra-class correlation coefficient ≥ 0.70). The metrics differentiated well between patients with varying disease severity levels. In conclusion, actigraphy-derived metrics of patients' walking bouts correlate significantly with 6MWD, BDI and physical impacts of PAH, indicating the utility of actigraphy in facilitating continuous monitoring of exercise capacity in adult patients with PAH.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT03078907; URL: clinicaltrials.gov.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70097"},"PeriodicalIF":2.2,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144161960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arteriovenous Oxygen Content Difference: A Diagnostic Predictor for Preselecting Invasive Treatment in Congenital Heart Disease-Related Pulmonary Arterial Hypertension.","authors":"Ashfaq Ahmad, Songlin Zhang, Lingling Li, Xiaoyu Wang, Yajuan Du, Ting Liu, Fenling Fan","doi":"10.1002/pul2.70091","DOIUrl":"10.1002/pul2.70091","url":null,"abstract":"<p><p>Patients with congenital heart disease-related pulmonary arterial hypertension (CHD-PAH) often require regular follow-up through invasive right heart catheterization (RHC) to assess disease progression and potential interventions. This study aims to evaluate the relationship between arteriovenous oxygen content difference (Ca-vO₂) and RHC parameters to identify blood gas parameters that can aid in a clue about preselecting patients with CHD-PAH for follow-up RHC and potential surgical or percutaneous shunt closure. In this study, a total of 137 adult CHD-PAH patients were retrospectively enrolled between September 2019 and May 2024. The patients were divided into two groups based on their Qp/Qs ratio (< 1.5 or ≥ 1.5). Key parameters such as Ca-vO₂, 6-min walk distance (6MWD), TAPSE, and IVC diameter were correlated with RHC parameters such as mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), and pulmonary capillary wedge pressure (PCWP) and compared across groups with Qp/Qs < 1.5 and ≥ 1.5. Statistical analysis included Pearson's correlation, logistic regression analysis, and receiver operator characteristic (ROC) curve to determine the predictors for shunt severity. The study enrolled 80 patients with CHD-related PAH in the final evaluation, with a mean age of 41 ± 15 years. Ca-vO₂ exhibits a significant positive correlation with RHC parameters, notably with mPAP (<i>r</i> = 0.524, <i>p</i> < 0.0001) and a negative correlation with Qp/Qs (<i>r</i> = -0.463, <i>p</i> = 0.04). Moreover, Ca-vO₂ emerged as a significant diagnostic predictor with an optimal cutoff value of < 4.3 mmol/L (AUC = 0.71, sensitivity 88.8%, specificity 53.4%). Other noninvasive parameters such as 6MWD, TAPSE, and IVC diameter with AUCs of 0.87, 0.83, and 0.85, respectively, also demonstrated a strong predictive value. Ca-vO₂ correlates well with CHD-PAH severity and can serve as a preselecting marker for invasive follow-up in CHD-related PAH. Other noninvasive measures such as 6MWD, TAPSE, and IVC diameter show stronger predictive value for assessing shunt severity.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70091"},"PeriodicalIF":2.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post- and Precapillary Pulmonary Hypertension: A Propensity Score-Matched Analysis From the Hellenic Pulmonary Hypertension Registry.","authors":"Georgios E Papadopoulos, Alexandra Arvanitaki, Sophia-Anastasia Mouratoglou, Panagiotis Gourgiotis, Thomas Chrysochoidis-Trantas, Athena Mpatsouli, Aris Bechlioulis, Aikaterini Naka, Eftychia Demerouti, Panagiotis Karyofyllis, Dimitrios Tsiapras, Anastasia Anthi, Athanasios Manginas, Antonios Ziakas, Stephan Rosenkranz, George Giannakoulas","doi":"10.1002/pul2.70099","DOIUrl":"https://doi.org/10.1002/pul2.70099","url":null,"abstract":"<p><p>Combined post- and precapillary pulmonary hypertension (CpcPH) comprises the most severe form of postcapillary PH. A severe precapillary component (pulmonary vascular resistance [PVR] > 5 WU) is critical for therapeutic decisions. Current treatment guidelines focus on optimizing underlying cardiac disease, while there are conflicting data regarding the efficacy and safety of pulmonary arterial hypertension (PAH) drugs in selected patients. This study examines the impact of PVR > 5 WU on survival in heart failure with preserved ejection fraction (HFpEF) and CpcPH and evaluates the effect of treatment with phosphodiesterase 5 inhibitors (PDE5is) on clinical and hemodynamic parameters and on prognosis. The Hellenic Pulmonary Hypertension Registry (HOPE) enrolls patients from all PH groups in Greece. This study focuses on Group 2 CpcPH patients with HFpEF. Propensity score matching was performed to reduce the risk of bias in the treatment selection and potential confounders. Kaplan-Meier curve was used to estimate 5-year survival, and the log-rank test was used for the comparisons. A total of 98 patients were included, with a median follow-up of 2.9 years. PVR > 5 WU and age were independently associated with worse survival ([HR 2.15, 95% CI 1.13-4.83, <i>p</i> = 0.04], [HR 1.07, 95% CI 1.03-1.13, <i>p</i> = 0.003], respectively). Propensity-matched cohort analysis indicated that PDE5i treatment was associated with a significant reduction in PVR at follow-up (from median [IQR] 4.89 [1.9] WU to 3.1 [2.0] WU, <i>p</i> = 0.04) and a trend towards improved survival. Severe precapillary component is associated with impaired prognosis in CpcPH. While PDE5i treatment shows promise in improving hemodynamic outcomes, its effect on long-term survival requires further investigation.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70099"},"PeriodicalIF":2.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated Bi-Ventricular Segmentation and Regional Cardiac Wall Motion Analysis for Rat Models of Pulmonary Hypertension.","authors":"Marili Niglas, Nicoleta Baxan, Ali Ashek, Lin Zhao, Jinming Duan, Declan O'Regan, Timothy J W Dawes, Chen Nien-Chen, Chongyang Xie, Wenjia Bai, Lan Zhao","doi":"10.1002/pul2.70092","DOIUrl":"10.1002/pul2.70092","url":null,"abstract":"<p><p>Artificial intelligence-based cardiac motion mapping offers predictive insights into pulmonary hypertension (PH) disease progression and its impact on the heart. We proposed an automated deep learning pipeline for bi-ventricular segmentation and 3D wall motion analysis in PH rodent models for bridging the clinical developments. A data set of 163 short-axis cine cardiac magnetic resonance scans were collected longitudinally from monocrotaline (MCT) and Sugen-hypoxia (SuHx) PH rats and used for training a fully convolutional network for automated segmentation. The model produced an accurate annotation in < 1 s for each scan (Dice metric > 0.92). High-resolution atlas fitting was performed to produce 3D cardiac mesh models and calculate the regional wall motion between end-diastole and end-systole. Prominent right ventricular hypokinesia was observed in PH rats (-37.7% ± 12.2 MCT; -38.6% ± 6.9 SuHx) compared to healthy controls, attributed primarily to the loss in basal longitudinal and apical radial motion. This automated bi-ventricular rat-specific pipeline provided an efficient and novel translational tool for rodent studies in alignment with clinical cardiac imaging AI developments.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70092"},"PeriodicalIF":2.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial Features Along the Pulmonary Vascular Tree in Chronic Thromboembolic Pulmonary Hypertension: Distinctive or Shared Facets?","authors":"Janne Verhaegen, Lynn Willems, Allard Wagenaar, Ruben Spreuwers, Nessrine Dahdah, Lucia Aversa, Tom Verbelen, Marion Delcroix, Rozenn Quarck","doi":"10.1002/pul2.70096","DOIUrl":"10.1002/pul2.70096","url":null,"abstract":"<p><p>Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of pulmonary embolism, characterized by the presence of organized fibro-thrombotic material that partially or fully obstructs the lumen of large pulmonary arteries, microvasculopathy, and enlargement of the bronchial systemic vessels. The precise mechanisms underlying CTEPH remain unclear. However, defective angiogenesis and altered pulmonary arterial endothelial cell (PAEC) function may contribute to disease progression. Despite the observation of differences in histological features, shear stress and ischemia along the pulmonary vascular tree, the potential contribution of PAEC phenotype and function to these disparate aspects remains unexplored. Based on these observations, we postulated that angiogenic capacities and endothelial barrier function may contribute to disparities in histological features observed along the pulmonary vascular tree. We thus explored the histological characteristics of the pulmonary vascular tree using pulmonary arterial lesions obtained during pulmonary endarterectomy (PEA). We focused on the angiogenic vascular endothelial growth factor (VEGF)-A/VEGF receptor-2 (VEGFR2) axis and collagen 15A1 (COL15A1), a potential marker of endothelial cells of the systemic circulation. Concurrently, we examined In Vitro angiogenic properties and barrier function of PAECs derived from large and (sub)-segmental pulmonary arterial lesions. (Sub)-segmental pulmonary arterial lesions were abundantly recanalized by neovessels, paralleled by an enriched expression of VEGFR2. VEGF-A expression was more pronounced in large pulmonary arterial lesions. Nevertheless, no significant difference was discerned in In Vitro angiogenic capacities and barrier integrity of PAECs isolated from large and (sub)-segmental pulmonary arterial lesions. Importantly, our findings revealed the presence of endothelial cells (CD31⁺) expressing COL15A1, as well as CD31⁺ cells that did not express COL15A1. This suggests that endothelial cells from both systemic and pulmonary circulation contribute to lesion recanalization. Despite disparate in situ angiogenic cues in VEGF-A/VEGFR2 axis between large and (sub)-segmental pulmonary arterial lesions in CTEPH, In Vitro angiogenic capacities and barrier function remain unaltered.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70096"},"PeriodicalIF":2.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibiting Serotonin Synthesis for the Treatment of Pulmonary Arterial Hypertension.","authors":"Georg Hansmann, Michael Bader","doi":"10.1002/pul2.70100","DOIUrl":"10.1002/pul2.70100","url":null,"abstract":"","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70100"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of MiR-542-3p/Integrin-Linked Kinase/Myocardin Signaling Axis in Hypoxic Pulmonary Hypertension.","authors":"Linqing Li, Weining Zhou, Qingrong Ji, Xianzhao Zhang, Ni Yang, Kaiyou Song, Shunpeng Hu, Cunfei Liu, Zhihong Ou, Fengwei Zhang, Yuda Wei, Jiantong Hou","doi":"10.1002/pul2.70094","DOIUrl":"10.1002/pul2.70094","url":null,"abstract":"<p><p>Phenotypic transition of pulmonary artery smooth muscle cells (PASMCs) under hypoxic conditions, which in turn causes increased proliferation and migration capacity, is an important pathological process in Hypoxic pulmonary hypertension (HPH). Although research on the phenotypic transition of PASMCs has been ongoing, little is known about the specific molecular mechanisms underlying this process. Integrin-linked kinase (ILK) is one of the genes essential for maintaining the contractile phenotype of vascular smooth muscle cells (VSMCs). It has been shown that ILK is a target gene of MiR-542-3p, and overexpression of MiR-542-3p can promote apoptosis of osteosarcoma cells by downregulating the expression of ILK, and inhibit their cell proliferation, migration, and invasion. In this study we found that hypoxia upregulated MiR-542-3p expression, and MiR-542-3p mimics reduced ILK, Myocardin expression, and promote phenotypic transition in PASMCs. And, ILK was a direct target of MiR-542-3p in PASMCs. MiR-542-3p inhibitor reversed hypoxia-induced reduction of ILK and Myocardin expression in PASMCs, and phenotypic transition, proliferation, and migration of PASMCs. MiR-542-3p antagomir reversed hypoxia-induced pulmonary vascular remodeling and also reversed hypoxia-induced reduction in ILK, Myocardin expression, and phenotype transition in rat pulmonary arteries. Thus, our results suggest that hypoxia induced an increase in MiR-542-3p expression, which caused an increase in binding to ILK gene and negatively regulated ILK expression. This in turn, caused a decrease in Myocardin expression leading to phenotypic transition, proliferation, and increased migration of PASMCs, causing hypoxic pulmonary vascular remodeling and ultimately leading to HPH.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70094"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor Expression.","authors":"Benjamin J Dunmore, Nobuhiro Kikuchi, Wei Li, Paul D Upton, Nicholas W Morrell","doi":"10.1002/pul2.70095","DOIUrl":"10.1002/pul2.70095","url":null,"abstract":"<p><p>Activin-A is elevated in pulmonary arterial hypertension (PAH) patients, and reportedly suppresses BMPR-II. This suggests one mechanism of action for PAH drug, sotatercept, an activin-ligand trap. However, we were unable to confirm that activin-A reduces BMPR-II in pulmonary endothelial cells. Thus, it seems unlikely that sotatercept influences BMPR-II or PAH via this mechanism.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70095"},"PeriodicalIF":2.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PVRI International Conference 2025: Embracing Heterogeneity.","authors":"Navneet Singh, Katarina Zeder","doi":"10.1002/pul2.70093","DOIUrl":"10.1002/pul2.70093","url":null,"abstract":"","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 2","pages":"e70093"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}